Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines ()
Telomir Pharmaceuticals at a Crossroads: Merger Vote and Regulatory Hurdles Telomir Pharmaceuticals (NASDAQ: TELO) faces a pivotal moment as shareholders prepare to vote on a transformative merger with TELI Pharmaceuticals. This decision, coupled with ongoing regulatory compliance, will significantly shape the future of the preclinical-stage biotechnology company focused on therapies targeting cancer, aging, and age-related … Read more